This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rofstad, E. K. Search for Related Content PubMed PubMed Citation Articles by Rofstad, E. K.

Influence of Cellular Radiation Sensitivity on Local Tumor Control of Human Melanoma Xenografts Given Fractionated Radiation Treatment¹

Institute for Cancer Research and The Norwegian Cancer Society, The Norwegian Radium Hospital, Montebello, 0310 Oslo 3, Norway

The radiocurability of human melanoma xenografts was studied by treating tumors with multiple fractions of 2.0 Gy and using local tumor control at 180 days as end point. Three melanoma lines (E. F., G. E., M. F.) that are only weakly immunogenic in athymic nude mice (BALB/c-nu/nu/BOM) were selected for the study. The tumor radiocurability was found to differ considerably among the lines; the radiation doses required to achieve local control of 50% of the tumors irradiated (TCD₅₀s; mean ± SE) were 85.0 ± 4.7 Gy (E. F.), 60.3 ± 5.4 Gy (G. E.), and 99.3 ± 5.7 Gy (M. F.). The radiation sensitivity in vitro of cells isolated directly from tumors also differed significantly among the lines. The TCD₅₀ showed positive correlations with the surviving fraction after 2.0 Gy in vitro, the surviving fraction after two doses of 2.0 Gy (4-h interval) in vitro, and the surviving fraction after 4.0 Gy at a low dose rate (1.25 cGy/min) in vitro. Thus, the differences in tumor radiocurability among the lines were mainly a consequence of cellular differences in the capacity to repair radiation damage. Comparisons of measured TCD₅₀s with theoretical TCD₅₀s, calculated from cell-surviving fractions measured in vitro after radiation treatment in vitro or in vivo, suggested that other tumor parameters, e.g., rate of repopulation between radiation fractions, also had a significant impact on the TCD₅₀. However, this study strongly supports the assumptions that the surviving fraction at 2.0 Gy in vitro is a useful parameter for prediction of clinical tumor radiocurability.

¹ Financial support was received from The Norwegian Cancer Society.

² To whom requests for reprints should be addressed, at Department of Biophysics, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo 3, Norway.

Received 3/ 1/91. Accepted 6/ 4/91.

This article has been cited by other articles:

				E. K. Rofstad, K. Galappathi, B. Mathiesen, and E.-B. M. Ruud Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis Clin. Cancer Res., April 1, 2007; 13(7): 1971 - 1978. [Abstract] [Full Text] [PDF]

				M. Garcia-Barros, D. Lacorazza, H. Petrie, A. Haimovitz-Friedman, C. Cardon-Cardo, S. Nimer, Z. Fuks, and R. Kolesnick Host Acid Sphingomyelinase Regulates Microvascular Function Not Tumor Immunity Cancer Res., November 15, 2004; 64(22): 8285 - 8291. [Abstract] [Full Text] [PDF]

				R. Kolesnick and Z. Fuks Response to Comments on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis" Science, December 12, 2003; 302(5652): 1894e - 1894e. [Full Text] [PDF]

				W. K. Dahlberg, E. I. Azzam, Y. Yu, and J. B. Little Response of Human Tumor Cells of Varying Radiosensitivity and Radiocurability to Fractionated Irradiation Cancer Res., October 1, 1999; 59(20): 5365 - 5369. [Abstract] [Full Text] [PDF]